Tablets film coated Limistin 20 are shown for:

• prevention of cardiovascular diseases;
• reduction of risk of developing of a myocardial infarction;
• reduction of risk of developing of a stroke;
• reduction of risk of holding procedures of revascularization and stenocardia.
• reduction of risk of developing of a non-lethal myocardial infarction;
• reduction of risk of developing of a lethal and non-lethal stroke;
• reduction of risk of hospitalization in connection with stagnant heart failure.

Structure

Active ingredient: atorvastatin;

1 tablet supports an atorvastatin of calcium in terms of atorvastatin 10 mg or 20 mg, 40 mg;

Excipients: calcium carbonate; cellulose microcrystalline lactose monohydrate, sodium of a kroskarmelloz; polysorbate 80 hydroxypropyl cellulose; magnesium stearate of a hydroksipropilmetiltsellyuloz; propylene glycol; polyethyleneglycol-6000; talc of the titan dioxide (E 171) - tablets on 10 mg and 20 mg

Calcium a carbonate; cellulose microcrystalline lactose monohydrate, sodium of a kroskarmelloz; polysorbate 80 hydroxypropyl cellulose; magnesium stearate krospovidon; sodium lauryl sulfate; hydroksipropilmetiltsellyuloza; polyethyleneglycol-6000; talc of the titan dioxide (E 171) - tablets on 40 mg.

Contraindication

Active disease of a liver which can include steady increase in activity of hepatic transaminases of not clear etiology.

Hypersensitivity to any of components of this medicine.

Route of administration

before therapy hypercholesterolemia level against the background of the corresponding diet, to appoint the physical exercises and measures directed to degrowth of a body of patients with obesity and to carry out treatment of other diseases. During treatment atorvastatiny patients should adhere to a standard diet with the low content of cholesterol. To use medicament in a dose of 10-80 mg of 1 times a day daily, at any time, irrespective of meal. The starting and maintenance dose can be individualized according to the H-LPNP initial level, problems of therapy and its efficiency. In 2-4 weeks after an initiation of treatment and/or the lipidogramm should define dose adjustments of an atorvastatin and according to it to correct a dose.

Feature of use

Pregnant

it is not applied.

Children

Since 10 years.

Drivers

is Carried out by very insignificant influence on speed of response at control of motor transport or work with other mechanisms.

Overdose

Specific treatment of overdose of an atorvastatin. In case of overdose of the patient it is necessary to treat symptomatically and if necessary to take the supporting measures. For high extent of linking of medicament with proteins of plasma should not expect considerable strengthening of clearance of an atorvastatin by means of a hemodialysis.

Atorvastatin in general is well had by

.

treat undesirable reactions: thorax pain, face edema, fever, asthenia, muscle tension of a neck, weakness, photosensitization, generalized hypostases, indisposition, pyrexia, peripheral hypostases.

Interaction

Risk of development of a myopathy during treatment by statines increases in case of simultaneous use of derivatives of fibroyevy acid, lipidomodifikatsiyny doses of Niacinum, cyclosporine or powerful CYP inhibitors 3A4 (for example a klaritromitsina, inhibitors of HIV protease and an itrakonazol).

Grapefruit juice. Contains one or more components which inhibit CYP 3A4 and can increase concentration of an atorvastatin in blood plasma, especially at excess consumption of grapefruit juice (more than 1.2 liters a day).

Atorvastatin and his metabolites are OATP1B1 conveyor substrates. OATP1B1 inhibitors (for example cyclosporine) can increase bioavailability of an atorvastatin. The AUC value of an atorvastatin considerably increased at simultaneous use of an atorvastatin in a dose of 10 mg and cyclosporine in a dose of 5.2 mg/kg/days in comparison with use only of an atorvastatin. It is necessary to avoid simultaneous use of an atorvastatin and cyclosporine.

to Store

in original packing at a temperature not above 30 °C.

to Store

out of children's reach.

Expiration date - 2 years.